BWT Pharmacy & Biotech

Dicerna Pharmaceuticals, Inc. is a leading biopharmaceutical company based in Lexington. They specialize in utilizing ribonucleic acid interference (RNAi) technology to develop innovative medicines that target disease-causing genes. With a focus on gene silencing, Dicerna Pharmaceuticals is dedicated to advancing treatments that address the root causes of various diseases. Their cutting-edge approach aims to provide effective solutions for patients in need of novel therapeutic options. Generated from their website's infomation

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in targeted protein degradation. Their innovative approach, known as Targeted Protein Degradation (TPD), aims to develop a new generation of medicines for treating various diseases. Through their TORPEDO platform and focus on target selection, C4 Therapeutics is dedicated to transforming lives by degrading disease-causing proteins. With a strong leadership team, board of directors, and scientific advisory board, C4 Therapeutics is committed to advancing their pipeline of therapies, including CFT7455, CFT1946, and CFT8919. They also collaborate with industry partners such as Roche, Biogen, Betta Merck, and others to further their research and development efforts. At C4 Therapeutics, their values, people, and dedication to scientific progress drive their mission to revolutionize the treatment of diseases through targeted protein degradation.Generated from the website

Headquartered in Cambridge, Mass., Biogen Idec specializes in the field of biotechnology. Its core capabilities include drug discovery, research and development. The company s focus is the development of products related to oncology, neurology and immunology. Among the company s products are treatments for B-cell, non-Hodgkin s lymphomas; a treatment for relapsing forms of multiple sclerosis; and a treatment for psoriasis and psoriatic arthritis. In addition, the company has several licensed and dedicated bulk-manufacturing facilities engaged in protein manufacturing. James C. Mullen has been the chief executive officer of Biogen Indec for more than two years. He has been with the drug and biotechnology company for over 17 years. Mullen earned a BS degree from Rensselaer Polytech, and a MBA from Villanova. The company maintains research centers in Cambridge, Mass., and San Diego. Biogen Idec has additional offices in Canada, Australia, Japan and Europe, including international headquarters in Zug, Switzerland. The company currently employs approximately 3,400 people worldwide.